News - Page 10 of 13 - Leukaemia Care

11th March 2019

Scottish Medicines Consortium has not approved the use of Tisagenlecleucel-T for diffuse large-B cell lymphoma (DLBCL)

Today, the Scottish Medicines Consortium (SMC) has not approved the use of Tisagenlecleucel-T (brand name Kymriah) on the NHS in Scotland for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of chimeric antigen receptor (CAR) T-cell therapy and is manufactured by Novartis.

11th March 2019

Liposomal cytarabine with daunorubicin approved for use in Scotland for t-AML and AML-MRC

The Scottish Medicines Consortium (SMC) has today recommended the use of liposomal cytarabine with daunorubicin to treat previously untreated therapy-related AML (t-AML) and AML with myelodysplastic changes (AML-MRC).

11th February 2019

Scottish Medicines Consortium approves Kymriah to be funded for use on the NHS in Scotland

Kymriah is a brand of CAR-T therapy, a pioneering new treatment for blood cancer patients. Find out more about the approval, and who it will benefit, here.

18th January 2019

NICE approves venetoclax (VENCLYXTO) with rituximab for previously treated chronic lymphocytic leukaemia (CLL) patients

NHS England are to make the first targeted CLL chemotherapy-free combination treatment of a fixed duration available through routine commissioning to treat patients relapsing or failing a first treatment

14th January 2019

Arsenic trioxide for APL in Scotland

The Scottish Medicines Consortium (SMC) have today announced that arsenic trioxide is not recommended for NHS patients in Scotland. Find out more about this decision and how it affects acute promyelocytic leukaemia (APL) patients.

19th December 2018

Liposomal cytarabine and daunorubicin approved by NICE

The National Institute of Health and Care Excellence (NICE) have today recommended the use of liposomal cytarabine with daunorubicin to treat previously untreated therapy-related AML and AML with myelodysplastic changes.

11th December 2018

Axicabtegene ciloleucel approved by NICE

Today, the National Institute for Health and Care Excellence (NICE) has approved the use of axicabtagene ciloleucel (brand name Yescarta) to be funded for use on the NHS in England. It will be available for patients with diffuse large B-cell lymphoma (DLBCL) and primary mestinal B-cell lymphoma (PMBL), after they have tried two other systemic therapies.

5th November 2018

Celebrity christmas card auction goes live!

A unique chance to own some fantastic autographs!

2nd November 2018

GBW hosts a bake-off for Leukaemia Care

Midlands marketing agency Gough Bailey Wright (GBW) has raised over £100 for Leukaemia Care, by hosting its annual bake sale.

5th October 2018

Leukaemia Care response: gemtuzumab ozogamicin

The National Institute of Health and Care Excellence (NICE) have today recommended the use of gemtuzumab ozogamicin to treat previously untreated CD33 positive acute myeloid leukaemia (AML), except for acute promyelocytic leukaemia (APL or APML).